{"schema_version":"secwatch.filing_event.v1","accession":"0001459839-23-000058","form_type":"8-K","ticker":"SIBN","cik":"0001459839","company_name":"SI-BONE, Inc.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.931269+00:00","generated_at":"2026-06-16T04:51:46.705901+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"SI-BONE Q1 revenue $32.7M (+46% YoY), raises FY2023 guidance to $128-131M","bullets":["Record worldwide revenue $32.7M (+46% YoY); US revenue $30.5M (+50% YoY).","Net loss improved to $11.1M ($0.32/diluted share) from $17.4M ($0.52) a year ago.","Gross margin 82% (down from 87%) due to product mix, new implants, and higher freight/depreciation.","FY2023 revenue guidance raised to $128-131M, implying 20-23% annual growth.","Over 950 active US surgeons (+40% YoY); cash $86M, borrowings $35.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001459839-23-000058","json":"https://secwatch.observer/filing/0001459839-23-000058.json","markdown":"https://secwatch.observer/filing/0001459839-23-000058.md","text":"https://secwatch.observer/filing/0001459839-23-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1459839/000145983923000058/0001459839-23-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1459839/000145983923000058/sibn-20230501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T04:51:46.705901+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"75c8ea158d6a770b99a232e26a45ae99a65591ab","claim":"SI-BONE, Inc. reported fiscal year 2023 results: revenue $128 million to $131 million. Guidance raised.","evidence_excerpt":"SI-BONE is updating its 2023 worldwide revenue guidance to be in the range of $128 million to $131 million, implying growth of approximately 20% to 23%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1459839/000145983923000058/0001459839-23-000058-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023"},{"label":"Revenue","value":"$128 million to $131 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"8881f7b75c915a382a788bb9e5866d55ae3fcb16","claim":"SI-BONE, Inc. reported the quarter ended March 31, 2023 results: revenue $32.7 million.","evidence_excerpt":"musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2023. Recent Highlights • Record world wide revenue of $32.7 million for the first quarter 2023, representing approximately 46% increase over the corresponding period in 2022 • Record U.S. revenue of $30.5 million for the first quarter 2023,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1459839/000145983923000058/0001459839-23-000058-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$32.7 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}